Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis ends Diovan, Lotrel sales contract

Executive Summary

Novartis is bolstering internal resources for the antihypertensives Diovan and Lotrel following termination of sales contract with PDI, company says. Current promotion by PDI of valsartan and amlodipine/benazepril with 300 reps will end effective March 16, PDI announces Feb. 18. Novartis had already scaled back the contract from 518 reps (1"The Pink Sheet" Jan. 5, 2004, In Brief)...

You may also be interested in...

Novartis reduces PDI sales contract

Novartis reduces its contract with PDI for next year to 300 reps, down from 518 in 2003. The contract sales organization will support the sale of the antihypertensives Diovan and Lotrel but will no longer sell Lotensin, which will go off patent in February. Novartis upped its support of its hypertension drugs with the launch of a blood pressure awareness campaign in August (1"The Pink Sheet" Aug. 18, 2003, In Brief)...

J&J Helping Out Vulnerable Children With UK Calpol Campaign

In a recent PR campaign for Calpol in the UK, Johnson & Johnson Consumer Health partnered with children’s charity NSPCC to raise awareness of the latter's helpline. HBW Insight speaks exclusively to J&J's head of Marketing for Northern Europe at J&J Consumer Health, Hannah French.

EMA Stands By Suspension Of Ranitidine

Suspension of heartburn remedy ranitidine looming in the EU as the European Medicines Agency stands by its original decision.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts